Association of fibrillin-3 and transcription factor-7-like 2 gene variants with metabolic phenotypes in PCOS

Obesity

Volumn 20, Issue 6, 2012, Pages 1273-1278

  Yalamanchi, Sudha K ^a   Sam, Susan ^b   Cardenas, Maria O ^a   Holaday, Louisa W ^a   Urbanek, Margrit ^a   Dunaif, Andrea ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRILLIN; FIBRILLIN 3; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; FBN3 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLUCONEOGENESIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; METABOLISM; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; TCF7L2 GENE;

ADOLESCENT; ADULT; ALLELES; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MICROFILAMENT PROTEINS; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; YOUNG ADULT;

EID: 84861572447     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.400     Document Type: Article

References (40)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
2. Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
4. Ehrmann DA, Liljenquist DR, Kasza K et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53.
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
6. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007;3:103-111.
7. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 1998;95:14956-14960.
8. Urbanek M, Sam S, Legro RS, Dunaif A. Identification of a PCOS susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab 2007;92:4191-4198.
9. Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323.
10. Biyasheva A, Legro RS, Dunaif A, Urbanek M. Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J Clin Endocrinol Metab 2009;94:2617-2625.
11. Lyssenko V, Lupi R, Marchetti P et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163.
12. Hirschhorn JN. Genomewide association studies-illuminating biologic pathways. N Engl J Med 2009;360:1699-1701.
13. Yki-Järvinen H. Insulin sensitivity during the menstrual cycle. J Clin Endocrinol Metab 1984;59:350-353.
14. Toth EL, Suthijumroon A, Crockford PM, Ryan EA. Insulin action does not change during the menstrual cycle in normal women. J Clin Endocrinol Metab 1987;64:74-80.
15. Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurement of abdominal and visceral fat with computed tomography and dual-energy X-ray absorptiometry. Am J Clin Nutr 1995;61:274-278.
16. Dunaif A, Segal KR, Shelley DR et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257-1266.
17. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:E392-E399.
18. Albu JB, Curi M, Shur M et al. Systemic resistance to the antilipolytic effect of insulin in black and white women with visceral obesity. Am J Physiol 1999;277:E551-E560.
19. Maggs DG, Buchanan TA, Burant CF et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-185.
20. Ehrmann DA, Sturis J, Byrne MM et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-527.
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-E223.
22. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-1467.
23. Liu PH, Chang YC, Jiang YD et al. Genetic variants of TCF7L2 are associated with insulin resistance and related metabolic phenotypes in Taiwanese adolescents and Caucasian young adults. J Clin Endocrinol Metab 2009;94:3575-3582.
24. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005;280:1457-1464.
25. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-480.
26. Cauchi S, Meyre D, Dina C et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006;55: 2903-2908.
27. Prokunina-Olsson L, Hall JL. Evidence for neuroendocrine function of a unique splicing form of TCF7L2 in human brain, islets and gut. Diabetologia 2010;53:712-716.
28. Kenigsberg S, Bentov Y, Chalifa-Caspi V et al. Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. Mol Hum Reprod 2009;15:89-103.
29. Jansen E, Laven JS, Dommerholt HB et al. Abnormal gene expression profiles in human ovaries from polycystic ovary syndrome patients. Mol Endocrinol 2004;18:3050-3063.
30. Cortón M, Botella-Carretero JI, Benguría A et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:328-337.
31. Amir AL, Barua M, McKnight NC et al. A direct ?-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem 2003;278:30828-30834.
32. Philibert P, Biason-Lauber A, Gueorguieva I et al. Molecular analysis of WNT4 gene in four adolescent girls with mullerian duct abnormality and hyperandrogenism (atypical Mayer-Rokitansky-Küster-Hauser syndrome). Fertil Steril 2011;95:2683-2686.
33. Natali A, Toschi E, Camastra S et al. Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 2000;43:1266-1272.
34. Hucking K, Watanabe RM, Stefanovski D, Bergman RN. OGTT-derived measures of insulin sensitivity are confounded by factors other than insulin sensitivity iItself. Obesity 2008;16:1938-1945.
35. Ramirez F, Sakai LY, Dietz HC, Rifkin DB. Fibrillin microfibrils: multipurpose extracellular networks in organismal physiology. Physiol Genomics 2004;19:151-154.
36. Jordan CD, Bohling SD, Charbonneau NL, Sakai LY. Fibrillins in adult human ovary and polycystic ovary syndrome: is fibrillin-3 affected in PCOS? J Histochem Cytochem 2010;58:903-915.
37. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008;14:367-378.
38. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002;23: 787-823.
39. Flanagan JN, Linder K, Mejhert N et al. Role of follistatin in promoting adipogenesis in women. J Clin Endocrinol Metab 2009;94:3003-3009.
40. Mukherjee A, Sidis Y, Mahan A et al. FSTL3 deletion reveals roles for TGFbeta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci USA 2007;104:1348-1353.